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Abstract
The success of nucleoside reverse transcriptase inhibitors (NRTIs) in treating HIV-1 infection and
reducing mother-to-child transmission of the virus during pregnancy is accompanied by evidence
that NRTIs cause long-term health risks for cancer and mitochondrial disease. Thus, agents that
mitigate toxicities of the current combination drug therapies are needed. Previous work had shown
that the NRTI-drug pair zidovudine (AZT)–didanosine (ddI) was highly cytotoxic and mutagenic;
thus, we conducted preliminary studies to investigate the ability of the active moiety of amifostine,
WR1065, to protect against the deleterious effects of this NRTI-drug pair. In TK6 cells exposed to
100 μM AZT-ddI (equimolar) for 3 days with or without 150 μM WR1065, WR1065 enhanced
long-term cell survival and significantly reduced AZT-ddI-induced mutations. Follow-up studies
were conducted to determine if coexposure to AZT and WR1065 abrogated the antiretroviral
efficacy of AZT. In human T-cell blasts infected with HIV-1 in culture, inhibition of p24 protein
production was observed in cells treated with 10 μM AZT in the absence or presence of 5–1,000
μM WR1065. Surprisingly, WR1065 alone exhibited dose-related inhibition of HIV-1 p24 protein
production. WR1065 also had antiviral efficacy against three species of adenovirus and influenza
A and B. Intracellular levels of unbound WR1065 were measured following in vitro/in vivo drug
exposure. These pilot study results indicate that WR1065, at low intracellular levels, has
cytoprotective and antimutagenic activities against the most mutagenic pair of NRTIs and has
broad spectrum anti-viral effects. These findings suggest that the activities have a possible
common mode of action that merits further investigation.
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Zidovudine (AZT or 3′-azido-2′,3′-dideoxythymidine) was the first nucleoside reverse
transcriptase inhibitor (NRTI) used to treat HIV-1 infection and to reduce vertical
transmission of the virus during pregnancy, and the largest body of data showing the
potential for NRTIs to induce long-term side effects pertains to AZT (reviewed in [IARC,
2000; Wutzler and Thust, 2001; Dagan et al., 2002; Poirier et al., 2004; NTP, 2006; Kohler
and Lewis, 2007; Walker and Poirier, 2007]). Phillips et al. [1991] reported that in vivo
exposure of mice to AZT caused significant increases in micronucleated cells in bone
marrow; since then additional studies have described the DNA damaging effects,
clastogenicity, mutagenicity, and carcinogenicity of AZT and other NRTIs in animal models
and humans [Olivero et al., 1997, 1999; Bonnet et al., 2004; Poirier et al., 2004; Brock et al.
2006; NTP, 2006; Escobar et al., 2007; Meng et al., 2007; Walker et al., 2007; Witt et al.,
2007]. Previous work showed that in vitro and in vivo exposure of cells to AZT caused
significant increases in mutations in reporter genes and in genes associated with neoplastic
transformation (reviewed in [Walker and Poirier, 2007]). The combined use of AZT and a
second NRTI enhanced cellular DNA incorporation of AZT and induction of mutations in
the hypoxanthine-guanine phosphoribosyltransferase (HPRT) reporter gene compared with
the responses from single NRTIs following in vitro exposure of human TK6 lymphoblastoid
cells or in utero exposure of human infants [Meng et al., 2000, 2007; Escobar et al., 2007].
In spite of these potential toxicities, NRTI-based combinatorial drug therapy in the form of
highly active antiretroviral therapy continues to be the most successful regimen for
controlling HIV-1 infection and the progression of AIDS-associated symptoms, and
reducing mother-to-child transmission of HIV-1 during pregnancy [Watts, 2006; Thorne and
Newell, 2007]. Because NRTIs are likely to remain the backbone of HIV therapy for the
foreseeable future, investigations of treatment options to minimize toxicities are a necessity
[Foster and Lyall, 2008]. Potential options for mitigating the additive/synergistic cytotoxic
and mutagenic effects of NRTI drug combinations are limited, and include the use of less
toxic drug combinations, the addition of cytoprotective/anti-mutagenic agents to the
currently used drug cocktails, or the development of alternative antiviral drugs with reduced
toxicity [Walker and Poirier, 2007].
In the 1950s through the 1970s, a class of phosphorothioate drugs known informally as
aminothiols was developed for use by the military as radioprotective compounds [Davidson
et al., 1980]. Amifostine (WR2721) was one of the most successful drugs developed and
tested; it is an organic thiophosphate that selectively protects normal tissues, but not most
tumor cells, against the cytotoxicity of ionizing radiation. Amifostine has the chemical name
S-2-(3-aminopropyl)-aminoethyl phosphorothioic acid and is a prodrug that is
dephosphorylated to the active free thiol metabolite (WR1065) by alkaline phosphatase
located in the cell membrane of most cells of many species including man [Capizzi, 1996;
Grdina et al., 2000, 2002c; Khodarev et al., 2004; Kouvaris et al., 2007]. Following
dephosphorylation, WR1065 is rapidly taken into the cell where it may be metabolized
further to a symmetrical disulfide (WR33278) as well as other products [Grdina et al., 2000].
Investigations of the aminothiols have shown that their activity falls into several categories.
Their radioprotective capabilities have been well documented in in vitro and in vivo studies
demonstrating multifold protection against different types of radiation in a variety of model
systems and species (reviewed in [Grdina et al., 2000, 2002a]). More recent studies have
shown the capacity of amifostine, and some related compounds, to provide cytoprotection in
patients undergoing chemotherapy for head and neck cancers and small cell lung cancer
[reviewed in [Culy and Spencer, 2001; Block and Gyllenhaal, 2005]. Amifostine currently is
FDA approved and marketed as Ethyol® for use as a cytoprotective agent during the
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treatment of these and a growing number of cancer types. Grdina et al. [1989a,b] and
Kataoka et al. [1992] showed that amifostine also functions as an antimutagen, an anticancer
agent, and an antimetastatic agent. Grdina et al. [1992] demonstrated that the aminothiol,
WR151327, protected Hep2G cells against the DNA damaging effects of AZT; these
findings were significant because they extended the range of the antimutagenic activity of
the aminothiols from the DNA damage effects attributed to radiation, and some chemo-
therapeutic agents, to the broader range of DNA lesions associated with exposure to AZT as
a representative NRTI.
The use of less toxic antiretroviral drug combinations has been explored, and the narrow
range in the relative mutagenic potencies exhibited by individual NRTIs, or combinations of
NRTIs [Carter et al., 2007; Torres et al., 2007], led to current efforts to identify
cytoprotective and antimutagenic agents that could be used along with antiretroviral agents
to mitigate deleterious side effects of NRTI-based highly active antiretroviral therapy.
During the course of the pilot studies reported here, we showed that WR1065 had both
cytoprotective and antimutagenic activities against the synergistic toxicities of the most
highly mutagenic pair of NRTIs, AZT, and didanosine (ddI or 2′,3′-dideoxyinosine), in
cultured human lymphoblastoid cells. Extension of these studies to assess the potential
impact of WR1065 on the therapeutic efficacy of AZT in phytohemagglutinin-stimulated
primary human lymphocytes infected with HIV-1 in culture led to the discovery that
WR1065 alone had anti-HIV activity; further work showed that WR1065 inhibited
replication of three species of adenovirus and influenza A and B. The possibility of
overlapping modes of action for WR1065-mediated cytoprotective, antimutagenic, and
antiviral activities was considered in this report.
MATERIALS AND METHODS
Chemicals, Media, and Cells/Cell Lines
AZT and ddI were obtained from Sigma-Aldrich (St. Louis, MO) or Byron Chemical Co.
(Long Island City, NY), and were dissolved in sterile physiologically buffered saline
(Sigma-Aldrich) for cell treatments. Amifostine was purchased from Sigma-Aldrich and
WR1065 was acquired from the NCI Chemical Repository and was stored according to
instructions provided. HEPES, 6-thioguanine, cytidine, hypoxanthine, aminopterin,
thymidine, alkaline phosphatase, phytohemagglutinin (PHA), formaldehyde, Trypan blue,
and crystal violet were purchased from Sigma-Aldrich. For in vitro studies of TK6 cells, cell
culture components including RPMI 1640, L-glutamine, MEM nonessential amino acids,
and penicillin–streptomycin were obtained from BioWhittaker (Walkersville, MD), and FBS
was purchased from Biomeda (Foster City, CA). For in vitro studies of human peripheral
blood mononuclear cells (PBMCs), cell culture components included RPMI 1640 medium
(American Type Culture Collection, Manassas, VA), FBS (Hyclone, Logan, UT), penicillin/
streptomycin/glutamine (Invitrogen, Gaithersburg, MD), and recombinant human IL-2 (BD
Biosciences, San Jose, CA). For in vitro studies of adenovirus and influenza virus
replication, cell culture components including minimum essential medium, newborn calf
serum, penicillin–streptomycin, and L-glutamine were obtained from Invitrogen. Human
TK6 lymphoblastoid cells were from an established cell line [Liber and Thilly, 1982] and
were a kind gift from Dr. J. Patrick O’Neill (University of Vermont), whereas fresh human
PBMCs were obtained from the NIH Transfusion Center (Bethesda, MD) under a NIH
Human Studies Research Board approved protocol. A549 cells, MDCK cells, adenovirus
species, influenza A, and influenza B were obtained from the American Type Culture
Collection.
The absolute purity of the WR1065 used in the pilot studies presented below was uncertain.
WR1065 is sensitive to oxidation (as well as other reactions) and can undergo reaction to
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forms that appear to lack activities associated with the free thiol [North et al., 2000]. Prior to
the initiation of these pilot studies, WR1065 was weighed (mol wt. 134) and stored frozen in
RPMI 1640 medium as a 10 mg/ml working solution. However, the vial of lyophilized
WR1065 used in the experiments presented here had been opened briefly two or three times
on previous occasions, with the possibility that minimal oxidation may have occurred. The
HPLC apparatus used in one set of experiments was available on one occasion only, thus,
determination of the purity of the WR1065 used in these experiments was not feasible.
Accordingly, in the tables and figures in the Results section, the indicated concentrations of
WR1065 represent the maximum amount of active compound that could be present; the true
concentration of active compound might be less. Also, for concentrations of WR1065 of less
than 100 μM, estimates of the true efficacy of the aminothiol are limited by the fact that a
portion of the compound has been found to be inactivated by a variety of medium
components [Grdina et al., 2002a].
Cloning Efficiencies and HPRT Mutant Frequencies in TK6 Cells Exposed for 3 Days to
AZT-ddI With or Without WR1065
A T-cell cloning assay was performed with TK6 cells cultured in supplemented RPMI 1640
growth medium as described [Sussman et al., 1999]. Cells were grown and all assays were
performed using culture conditions that optimized cell viability, based upon Trypan blue
exclusion, to ensure that changes in cell viability or cloning efficiencies (CEs) were due to
the treatments and not to suboptimal cell culture conditions [Carter et al., 2007]. TK6 cells
were expanded in T-flasks, and 4 to 5 days before starting treatments, the cells were changed
to growth medium that contained CHAT [cytidine (C), hypoxanthine (H), aminopterin (A),
and thymidine (T)] for 48 hr, then to conditioned medium that contained THC for 24 hr to
reduce the spontaneous background HPRT mutant frequency [Liber and Thilly, 1982].
Conditioned medium was prepared 24 hr before needed, as follows. TK6 cells in log-phase
growth were diluted to 3 to 5 × 105 cells/ml with fresh medium. The next day, this medium
was removed and an additional 10% FBS (above that already in the medium) was added.
The conditioned medium was filter sterilized using a 0.45-μm filter to remove any cells and
mixed with freshly prepared RPMI 1640 growth medium to achieve a 50:50 ratio. Following
the exposures, cells were washed, resuspended, and subcultured in nonselective medium for
7 days. For CE measurements, a fraction of treated and vehicle-exposed cells from each
flask was plated at an average of two viable cells per well, in the presence of 4 × 104 lethally
irradiated TK6 “feeder” cells, in 96-well U-bottom microtiter dishes. Fourteen days later, the
plates were scored for positive colonies, based on morphology, size, and density. CEs were
calculated as described by Sussman et al. [1999], and expressed as the mean ± standard
deviation (SD).
The ability of WR1065 to prevent AZT-ddI-induced mutations was tested following
exposure of T-cells for 3 days to 0 or 100 μM AZT-ddI (equimolar), with or without 150 μM
WR1065 (n = 6 replicates/group). After a 7-day expression period, cells from each flask
were plated in 96-well U-bottom microtiter dishes in nonselective medium to measure CEs
and selective medium containing 6-thioguanine (1 μg/ml medium) to measure HPRT mutant
frequencies. Fourteen days after plating, the microtiter dishes were examined for colonies in
selective and nonselective medium. Observed HPRT mutant frequencies were calculated as
previously described [Sussman et al., 1999], and expressed as the mean ± SD. Experiments
were performed in duplicate, and data were combined for presentation here.
Inhibition of HIV-1p24 Protein Production by AZTand/or WR1065
An initial experiment was conducted to compare p24 protein production inhibition by AZT
with or without WR1065. Fresh human PBMCs were cultured in 96-well plates at a density
of 5 × 105 cells for 48 hr in RPMI 1640 medium with 10% fetal bovine serum, 10 U/ml
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human IL-2, 1% penicillin/streptomycin/glutamine, and 20 μg/ml PHA as a mitogen.
Proliferating T-cell blasts then were infected with HIV-1BZ-167 (S. Sharpe, New York
University, New York, NY) for 2 hr [Perno et al., 1988], washed to remove excess virus,
and incubated with 10 μM AZT, 1,000 μM WR1065, or 10 μM AZT plus 1,000 μM
WR1065 for 72 hr with no further changes in medium. Control groups included HIV-1
infected and uninfected PHA-stimulated T-cell blasts that were untreated. After 72 hr, cells
were harvested and the HIV-1 infection status was determined in the experimental and
control groups by measuring p24 protein using an ELISA kit (RETRO-TEK HIV-1, p24
Extended Range ELISA) (ZeptoMetrix, Buffalo, NY).
Based on our finding of apparent antiretroviral activity by WR1065 in this first experiment,
subsequent experiments were performed (using the above protocol) to define the dose-
response relationship between the concentration of WR1065 and p24 levels in HIV-1-
infected PHA-stimulated T-cell blasts. In the second experiment, cells were treated for 72 hr
with 10 μM AZT or 100, 330, or 1,000 μM WR1065. In the third experiment, HIV-1-
infected cells were treated for 72 hr with 10 μM AZT or 10, 33, or 66 μM WR1065. Note
that for experiments #1 and #2, aliquots of virus that had been stored previously at the NCI
were used; for experiment #3, newly obtained HIV-1BZ-167 (from the same source as above)
was used.
In parallel with these experiments, the degree of treatment-induced cytotoxicity was
assessed by measuring relative levels of cell viability in human T-cell blasts treated with
vehicle alone or drugs in the absence of HIV-1 infection. Cell viability was determined by
comparing the numbers of viable and nonviable cells using a hemocytometer and Trypan
blue exclusion.
Effects of WR1065 on the Replication of Human Adenoviruses or Influenza Viruses
Antiviral activities of WR1065 against adenoviruses were tested in A549 cells (alveolar type
II, derived from a human lung carcinoma) and against influenza A or influenza B in MDCK
cells (a canine kidney epithelial cell line) grown to near confluence in minimal essential
medium in six-well plates, using standard culture media and growth conditions
recommended for these cell lines (American Type Culture Collection). Aliquots of a given
virus were prepared at an estimated concentration of 1,000 plaque forming units (PFUs) in
100 μL; cells were infected with serial dilutions of these aliquots and virus was absorbed to
the cells for 1 hr at 37°C. After adsorption, cells were replenished with minimal essential
medium containing up to 100 μM WR1065. Cultures were maintained at 37°C in 5% CO2
for 7 days for adenovirus assays and 3 days for influenza virus assays. Postinfection,
infected cells were frozen and infectious virus yield titers in freeze-thawed preparations
were determined by plaque assay. WR1065 antiviral activity was evaluated using two
different dilutions of virus, which gave different infectious virus yields wherever possible.
To assess WR1065 effects upon A549 cell viability, uninfected A549 cells were grown in
flat-bottomed six-well plates until near 100% confluence and then refed with freshly
prepared medium with or without 150 μM WR1065. The cells were held for 5 to 7 days, and
cell viability was assessed by gross and microscopic evaluation of wells for evidence of cell
loss.
To estimate the amount of plaque reduction per unit dose of WR1065 for these antiviral
analyses, the average reduction in PFUs per unit dose of WR1065 at each administered dose
of WR1065 was calculated as follows: (average PFUs for vehicle-exposed cells − average
PFUs at dose Y WR1065) ÷ (dose Y (μM) of WR1065) = average plaque reduction effect
per unit dose WR1065.
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Intracellular Concentrations of WR1065 in Lymphocytes Following In Vitro or In Vivo
Treatment With Amifostine
The relationship between the dose of amifostine and the range of intracellular levels of
WR1065 was examined following in vitro exposure of mouse, rat, and human lymphocytes
and in vivo exposure of mice. Peripheral blood samples were collected from two of the
authors using vacutainer tubes containing sodium heparin, and PBMCs were separated on
ficol solution, washed, and cultured in RPMI 1640 medium including PHA as described
earlier. Previously described techniques were used for isolating lymphocytes and culturing
T-cells from mice and rats [Torres et al., 2007]. Briefly, the animals were euthanized by
CO2 asphyxiation, spleens were removed aseptically and macerated, single cell suspensions
were layered onto ficol solution, and washed cells (i) were cultured in RPMI 1640 medium
in the presence of growth factor and mitogen (concanavalin A) for in vitro exposure to
amifostine or (ii) were frozen following in vivo exposure of mice to amifostine. Animals
were housed under standard conditions [Torres et al., 2007] and the procedures using
rodents were approved by the Institutional Animal Care and Use Committee of Lovelace
Respiratory Research Institute; procedures using human lymphocytes were approved by an
Institutional Review Board.
For the in vitro exposures, primary mouse, rat, and human lymphocytes, maintained in T-25
flasks containing supplemented RPMI 1640 medium, were exposed for 1 or 2 hr with 0, 10,
50, or 100 μM amifostine that was dephosphorylated by preincubation with alkaline
phosphatase (n = 2–4 flasks/time point and concentration) [Livesey et al., 1988].
Dephosphorylated amifostine was used in these experiments, as opposed to WR1065,
because fresh WR1065 was not available. After treatment, cells were washed, concentrated,
snap frozen, and stored at −80°C until analysis. For in vivo exposures of mice, individual
animals were treated by subcutaneous injection with 0, 15, or 30 mg/kg amifostine dissolved
in sterile saline (n = 3–4 mice/group), and animals were necropsied 2 hr later for isolation
and freezing of splenic lymphocytes as described.
On the day of analysis, the frozen cells were homogenized in water (20% w/v), precipitated
with an equal volume of perchloric acid–EDTA and centrifuged at 4°C, as described by
Pamujula et al. [2004]. The analysis of WR1065 was performed using a high-pressure liquid
chromatography method with electrochemical detection and previously described
chromatographic conditions [Srinivasan et al., 2002; Pamujula et al., 2004], except that the
signal was monitored on four channels and the 400 mV channel (which was the most
sensitive) was used for generating a standard curve. For each sample, the concentration of
WR1065 per million cells was determined by interpolating the peak areas to a standard
curve for WR1065 and analyses were performed in duplicate.
Statistical Analyses
Differences between individual treatment groups vs. controls, or paired sets of samples,
were determined by the Student’s t-test or Mann-Whitney U-statistic. In examining the
antiviral activities of WR1065 and/or AZT, the χ2 test was used to assess differences in the
proportions of HIV p24 protein production or infectious virus yields, and a multiple linear
regression was used to test trends in antiviral activity. Statistical analyses were performed
using SigmaStat (SSPSSC, Chicago, IL); P-values < 0.05 were considered significant.
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Effect of 3-Day Exposures to AZT-ddI, With or Without WR1065, on CEs and HPRT Mutant
Frequencies in TK6 Cells
Experiments were conducted to determine the potential impact of exposure to WR1065 (150
μM) on cytotoxic and mutagenic effects of AZT-ddI (100 μM each), the most mutagenic
pair of NRTIs tested to date [Carter et al., 2007], following 3-day treatments of TK6 cells
(Table I). No difference in average CEs between vehicle-exposed vs. WR1065-exposed cells
was observed, although there was a small nonsignificant decrease in the viability of
WR1065-treated cells (P = 0.3). In contrast, significant differences in CEs were observed
between vehicle- and AZT-ddI-exposed cells, with the relative cell survival for AZT-ddI-
exposed cells reduced to only 34% of control cells (P < 0.001), a finding consistent with the
reported cytotoxicity of this NRTI drug combination [Meng et al., 2000; Carter et al., 2007].
Exposure of TK6 cells to the combined drug treatment of AZT-ddI plus WR1065 increased
the relative cell survival to 52% of vehicle-exposed cells, a result that fell just short of a
significant increase in relative cell survival compared with treatment with AZT-ddI without
WR1065 (P = 0.06). These results are compatible with the reported activity of WR1065 as a
cytoprotective agent.
The ability of WR1065 to mitigate AZT-ddI-induced HPRT mutations was assessed in the
same pilot study. A minimal nonsignificant increase in mean HPRT mutant frequencies was
observed in cells exposed only to WR1065 (mutant frequency = 3.6 × 10−6) compared with
vehicle-exposed cells (mutant frequency = 2.8 × 10−6). AZT-ddI-exposed cells had
significantly increased mean HPRT mutant frequencies (mutant frequency = 12.1 × 10−6)
compared with all other groups (P < 0.05). Coexposure to AZT-ddI plus WR1065 (mutant
frequency = 4.2 × 10−6) abrogated the synergistic mutagenic effects of the NRTIs by at least
85% (P < 0.05) (Fig. 1). Notably, the increase in HPRT mutant frequencies observed in cells
exposed to AZT-ddI plus WR1065 was not significantly different from the background
HPRT mutant frequencies found in vehicle-exposed cells (P > 0.05), and approximated
closely the mutant frequencies of cells exposed to WR1065 alone. These findings
demonstrate the substantial efficacy of WR1065 as a protectant against AZT-ddI-associated
mutagenic effects.
Inhibition of HIV-1Replication by AZTand/or WR1065 Following Infection of Human T-Cell
Lymphocytes With HIV-1
The aforementioned findings led to investigation of the potential impact of WR1065 on the
antiretroviral efficacy of AZT. The production of HIV-1 p24 protein was examined in fresh
human PBMCs cultured with PHA to produce T-cell blasts, infected with HIV-1BZ-167 for 2
hr, washed, and then treated for 72 hr with AZT alone (10 μM), WR1065 alone (1,000 μM),
or AZT plus WR1065 at the same drug concentrations (Table II, Experiment 1). Uninfected
T-cell blasts served as controls for evaluation of drug toxicity (see later). PHA-stimulated
blasts uninfected with HIV-1, and cells that were infected but untreated, served as control
groups. Assessment of HIV-1 replication showed that 10 μM AZT resulted in 100%
inhibition of p24 protein production as determined by ELISA in the presence or absence of
WR1065. This experiment also revealed that 1,000 μM WR1065 provided ~100% inhibition
of p24 protein production when applied alone to HIV-1-infected T-cell blasts.
Additional experiments were designed to assess the relationship between the concentration
of WR1065 and p24 protein levels in HIV-1-infected PHA-stimulated human PBMCs. In a
second experiment, the estimated % inhibition of p24 production in cells treated with 100,
330, or 1,000 μM WR1065 was high across all three aminothiol concentrations (~95%) and
was similar to that provided by 10 μM AZT (Table II, Experiment 2). In a third experiment,
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10 μM AZT provided ~100% inhibition of HIV-1 replication, whereas, 5, 10, 33, or 66 μM
WR1065 exhibited dose-related inhibition ranging from ~77% at 5 μM to nearly 100% at 66
μM (Table II, Experiment 3). As noted earlier, different aliquots of HIV-1 virus (obtained
from the same source) were used in experiments #1 and #2 vs. experiment #3. Elevated p24
protein production in infected, untreated cells was observed in experiment #3 compared with
that of the previous two experiments (see Table II). Thus, comparisons between the percent
reductions in p24 protein production within each experiment can be made with confidence,
but comparisons between experiments should be made with caution. Yet, these combined
experiments showed that WR1065 significantly reduced p24 production even though a broad
range of WR1065 concentrations was tested, and the replicative capacity of the virus varied
between experiments. These findings support the conclusion that the aminothiol alone
inhibited HIV-1 replication. A companion report further examines the activity of WR1065
against HIV-1 in vitro and simian immunodeficiency virus ex vivo [Poirier et al.,
submitted].
To determine if some of the inhibition of virus replication might be due to WR1065-
mediated cytotoxicity, HIV-1-uninfected fresh PBMCs were cultured in 0, 1, 5, 10, 50, 100,
500, or 1,000 μM WR1065 for 72 hr, and cell viability was determined using Trypan blue
exclusion. These experiments showed that cell survival ranged from ~90% at 10 or 50 μM
WR1065 down to 73% at 500 μM WR1065 and 30% at 1,000 μM WR1065. The data
indicated that doses ≥100 μM showed cytotoxicity that may have been associated with some
HIV-1 growth inhibition, but at doses of 1–50 μM WR1065, there was no significant
contribution of cytotoxicity to the antiretroviral effects observed. Additional experiments
confirming and extending these observations are presented in a companion report [Poirier et
al., submitted].
WR1065-Mediated Inhibition of Adenovirus Replication in A549 Cells or Inhibition of
Influenza A and B Replication in MDCK Cells
The aforementioned findings led to investigations to determine the ability of WR1065 to
inhibit replication of viruses from other virus families including adenoviruses representing
species B, C, and E, and influenza A and B. The impact of WR1065 treatment upon the
replication of adenovirus type 7 of species B, adenovirus type 5 of species C, and adenovirus
type 4 of species E in A549 cell monolayers is presented in Table III. Ad7p (strain Gomen)
was used as a representative species B adenovirus associated with respiratory infections in
pediatric and military populations; Ad5p (strain Adenoid 75) was used as representative of
species C adenoviruses associated with upper respiratory infections in immunocompromised
patients; Ad4p (strain RI-67) was used as representative of species E adenoviruses
associated with conjunctivitis and respiratory infections in military populations. The results
of these studies demonstrated that WR1065 reduced infectious virus yields for the three
evaluated species of adenovirus. In these pilot studies, exposure to 100 μM WR1065
resulted in a significant reduction in PFUs in experiments where infected, untreated cells
had infectious virus yields greater than 50 × 106 PFU/ml. For experiments where infected,
untreated cells had infectious viral yields greater than 500 × 106 PFU/ml, exposure to 33 μM
WR1065 also had a significant antiviral effect. Nonsignificant reductions in PFUs were
observed in all other experiments and/or when lower doses of WR1065 were used (e.g., see
Fig. 2). These findings support the conclusion that WR1065 had antiviral activity against
these species of adenovirus.
To assess WR1065-mediated effects upon A549 cell viability, uninfected A549 cells were
incubated with 0, 10, 30, and 100 μM WR1065 to determine the effects of the drug upon cell
viability. A549 cells formed uniform monolayers with no evidence of grossly or
microscopically visible focal areas of cell death when incubated with any of the above
WR1065 concentrations for up to 7 days. These results demonstrate that these exposure
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concentrations of WR1065 lacked cytotoxic effects upon A549 cells in the absence of viral
infection.
Subsequently, WR1065 was evaluated for its ability to inhibit viral replication and
development of cytopathic effects in influenza A- or influenza B-infected MDCK cell
monolayers. Increasing doses of WR1065 resulted in significant trends in the reduction of
infectious virus yields for both influenza A and B virus strains (Table IV) (P < 0.05), but
pairwise comparisons between infectious virus yields in cells treated with a given dose of
WR1065 and infected, untreated control cells were not significant in these pilot experiments.
Efficacy appeared to be dependent upon both the viral strain being tested and the drug dose
administered. These findings support the conclusion that WR1065 had antiviral efficacy
against influenza A and influenza B.
As part of efforts to understand the effect of WR1065 on the inhibition of viral replication,
we estimated the plaque reduction efficacy per unit dose of WR1065 using data from
representative experiments performed with adenoviral- and influenza-infected cells (see
Table V). Five viruses were tested in two different epithelial cell types; in each experiment
the effect per unit dose of WR1065 was higher at the lowest dose tested and diminished as
the applied dose increased. The trend was observed across all experiments where multiple
dose levels were evaluated. Data for similar evaluations performed for HIV-infected cells
are not presented due to the fact that these pilot studies included relatively high doses of
WR1065; however, trends in WR1065-associated effects per unit dose similar to those
above (Table V) were observed in some low-dose experiments of HIV-1 replication
inhibition (data not shown).
As was noted the results for the HIV-1 experiments, comparisons of drug efficacy between
experiments using adenoviruses or influenza viruses should be made with caution. Although
every effort was made to ensure that each aliquot of the evaluated viruses had equal
replicative capacity, variations between aliquots were observed. Thus, comparisons of drug
inhibitory effects upon viral replication within one experiment can be done with confidence,
but comparisons between experiments should be made with caution because of the potential
for differences in viral replication capacity between experiments. Additional work will be
necessary to determine how well these in vitro experimental results predict in vivo drug
efficacy.
Intracellular Levels of Free WR1065 in Cytoplasm of Exposed Primary Lymphocytes
An important issue was the range in intracellular levels of WR1065 that occurred following
in vitro or in vivo treatment with WR1065, the free thiol of amifostine, that offered
cytoprotective, antimutagenic, and/or antiviral activities under the exposure conditions used
in the studies described earlier. To address this issue, pilot studies were performed to
measure intracellular levels of unbound WR1065 in primary mouse, rat, and human
lymphocytes at treatment levels of amifostine in cell culture medium previously found to
provide significant protection against mutations induced by AZT-ddI and significant
reduction in viral load in human cells in vitro. It should be noted that amifostine that had
been dephosphorylated via alkaline phosphatase immediately prior to use was applied in
these studies because fresh WR1065 was not available. Amounts of free WR1065 also were
measured in splenic lymphocytes isolated after subcutaneous injection of mice with
amifostine. These in vitro studies found an average concentration of free WR1065 of 32
pmol/106 cells in mouse and rat lymphocytes treated in culture with amifostine (Fig. 3),
levels that are well below the accumulated intracellular concentration of ~30 nmol
WR1065/106 cells found by Calabro-Jones et al. [1998] to produce significant cytotoxicity
in multiple types of cultured cells. Similar levels of unbound WR1065 were measured in
primary human lymphocytes exposed to dephosphorylated amifostine (data not shown), but
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the amount of WR1065 was more variable than that found in similarly treated rodent
lymphocytes. In amifostine-exposed mice, dose-related amounts of free WR1065 were
measured in splenic lymphocytes, with 56 ± 1 pmol/106 cells and 82 ± 17 pmol/106 cells
found 2 hr after subcutaneous injection with 15 or 30 mg amifostine/kg. WR1065 was not
detected in cells following in vitro or in vivo exposure to vehicle alone.
These studies also showed a marked reduction in the accumulation of intracellular free thiol
at exogenous doses above ~50 μM. These results are consistent with the observation that
transport of WR1065 into cells occurs by two processes, one of which is active and operates
at doses below ~50 μM, the second of which is passive and operates at WR1065 levels that
exceed 50 μM [Grdina et al., 1995].
DISCUSSION
The initial goal of this work was to investigate the ability of the aminothiol, WR1065, to
protect human cells against cytotoxic and mutagenic effects of NRTIs in vitro. These pilot
studies showed that exposure of human TK6 lymphoblastoid cells to AZT-ddI plus WR1065
for 3 days had antimutagenic effects and long-term cytoprotective effects as measured using
CEs, even though the doses of WR1065 used in these experiments were below those
previously shown to be cytoprotective [Grdina et al., 2002b]. Extension of this work
revealed that WR1065 had antiviral effects against HIV-1, three species of adenovirus, and
influenza A and influenza B. The antimutagenic and antiviral activities were associated with
low intracellular levels of WR1065, suggesting a common mode of action.
In assessing cytoprotective activity of WR1065, we chose to evaluate CEs instead of
assessing cell viability by Trypan blue exclusion because measurements of CE provide a
quantitative indication of the impact of drug exposure upon the functionality of genes
involved in the ability of cells to survive mild physical stress and to plate down, to reenter
the growth cycle, and to proliferate for a 14-day period. These studies showed that WR1065
provided long-term protection against AZT-ddI-induced cyto-toxicity and mutagenicity,
findings that are in agreement with the reported ability of WR1065 to protect cells/tissues
from the cytotoxic and mutagenic effects of radiation and chemotherapeutic agents [Grdina
et al., 2000, 2002c], and that extend the range of known lesions against which WR1065 has
efficacy as a protective agent.
A comparison of the degree of WR1065-mediated protection against mutagenesis found in
our pilot study compared with that reported previously shows that the ~85% reduction in
AZT-ddI-induced mutant frequencies in TK6 cells coexposed to WR1065 is similar to the
mutant frequency reductions found in lymphocytes of mice given amifostine before in vivo
exposure to gamma radiation or cyclophosphamide (i.e., 63 or 78% reduction in observed
Hprt mutant frequencies, respectively) [Grdina et al., 1985, 1999; Kataoka et al., 1996]. The
results of our AZT-ddI experiments support an earlier hypothesis that the effects of WR1065
on cell turnover rates led to enhanced DNA repair [Khodarev et al., 2004]; improved repair
would have several effects: (i) improved survival for a subset of cells because of the
prevention of lethal mutations, (ii) decreased cell viability for another subset because of the
loss of cells that could not repair the NRTI-induced damage successfully, and (iii) a
significant reduction in mutant frequencies.
The finding that WR1065 significantly reduced the mutagenicity of AZT-ddI in TK6 cells
led to follow-up studies of the potential impact of WR1065 on the antiretroviral efficacy of
AZT and the discovery that WR1065 alone reduced HIV-1 replication. The experiments
reported here did not allow us to draw conclusions about potential interactions between AZT
and WR1065 because, at the doses used, both drugs had substantial anti-HIV activity, and it
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was not possible to determine if one drug affected the efficacy of the other. The issue of
potential drug interactions is addressed in a companion report [Poirier et al., submitted]. Cell
viability studies conducted in parallel assays showed that WR1065-related toxicity increased
with escalating dose, but cytotoxicity was not sufficient to account for the observed
inhibition of viral p24 protein production. Optimal cell survival was achieved at doses of 10
and 50 μM, levels at which active transport of the drug into cells has been hypothesized to
occur [Grdina et al., 1995].
These antiviral studies then were extended to distinctly different viruses. Under a current
viral classification scheme
(http://www.virology.net/Big_Virology/BVFamilyGenome.html), HIV-1 is classified in the
family Retroviridae, part of the group of DNA and RNA reverse transcribing viruses. To
investigate further the potential antiviral activity of WR1065, we examined its effects upon
viral replication of adenovirus serotypes representative of species B, C, and E within the
genus Mastadenovirus in the family Adenoviridae, part of the group of DNA double-
stranded viruses, nucleic acid-type double-stranded DNA virus, and influenza A and B in the
family Ortho-myxoviridae, part of the group of RNA viruses, nucleic acid type (−) single-
stranded RNA viruses. WR1065, at concentrations of 100 μM and lower, reduced the
replication of the tested species of adenovirus, and also reduced the replication of influenza
A and B, with WR1065 having no observable toxicity over the course of treatment in A549
cells. In evaluating the results of these studies, it should be noted that the antiviral efficacy
of WR1065 was tested at concentrations of virus with differing infectious virus yields.
Significant antiviral efficacy was observed consistently across all experiments only for the
higher infectious virus yields and for the highest concentrations of WR1065 tested. The
inability to detect consistent antiviral efficacy at lower concentrations of virus and/or
WR1065 may reflect the small sample size used in these pilot studies and additional work
will be necessary to investigate these effects further.
As part of our efforts to understand the activity of WR1065 as an antiviral agent in greater
detail, we determined the effect per unit dose and also measured levels of free drug in
primary lymphocytes exposed in culture. Surprisingly, we found an inverse relationship
between the dose of WR1065 used in the studies of inhibition of adenovirus and influenza
virus replication and the effect per unit dose of WR1065 (Table V). Subsequent studies
showed that these antiviral effects were achieved at low levels of intracellular free drug. It
should be noted that the levels of bound drug were not measured; because bound drug may
be the active form, these latter studies are more informative for the ability to achieve
therapeutic intracellular drug levels than for the level of intracellular drug with antiviral and
antimutagenic activity.
The findings of both antimutagenic and antiviral activity of WR1065 support the hypothesis
that these effects involve a common drug mechanism. The antimutagenic mode of action of
the aminothiols including WR1065 has been investigated previously, and another body of
literature discusses potential modes of action for poly-amines, polyamine analogs, and thiol-
containing compounds as antiviral agents. A thorough review of these studies is beyond the
scope of this report, but some findings are informative for the pilot studies presented here.
WR1065 has been shown to have both high-dose and low-dose effects [Grdina et al., 2000,
2002c]. Cytoprotection is associated with high-dose exposures, and it is considered to be
optimal at doses near 4 mM and is attributed to WR1065’s activity as a free-radical
scavenger, whereas the drug’s antimutagenic effects are associated with low-dose exposures
around 100 μM or lower where changes in transcription factor binding, protein
phosphorylation levels, and gene expression have been described [Grdina, 2002c].
Interestingly, low intracellular levels of WR1065 have been shown to affect the
phosphorylation of topoisomerase II alpha, thereby, affecting its activity [Murley et al.,
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1997]. This enzyme is involved in host cell DNA replication and replication of HIV-1
[Freire et al., 2001] and effects upon its activity also could alter mutation induction by
delaying cell cycle progression to allow more time for DNA repair [Kondapi et al., 2005].
Both polyamines and thiol-containing compounds have been shown to have antiviral
activity. Ames and Dubin [1960] reported that polyamines inhibited replication of T4
bacteriophage. Mitchell et al. [1998] showed that WR1065 increased intracellular
spermidine levels in cells exposed in vitro. Such a change has been suggested to have
antimutagenic effects because of the DNA protective capacity of spermidine, and also could
result in antiviral effects because of changes in intracellular polyamine levels [Bachrach and
Rosenkovitch, 1972; Bachrach, 2007]. The precise mechanism(s) by which polyamines
induce DNA protective, antimutagenic, and antiviral effects are uncertain. Some studies
showed that polyamine metabolism by amine oxidases resulted in the formation of
aldehydes, aminoaldehydes, and oxidized polyamines that had broad spectrum antiviral
activity [Bachrach, 2007], and oxidation has been shown to reduce the activity of HIV-1
proteases [Davis et al., 1999]. It should be noted that WR1065 is metabolized in vitro to
cysteamine, acrolein, other aldehydes, and hydrogen peroxide by copper-dependent amine
oxidases present in serum [Meier and Issels, 1995]; however, oxidation metabolites of
WR1065 do not appear to be sufficient to explain the inhibitory effects of WR1065 upon
adenoviruses as shown in these pilot studies, because adenoviruses are resistant to many
virucidal compounds including many aldehydes that are effective inhibitors of other viruses
[Sauerbrei et al., 2007].
Several investigators have reported evidence that thiol-containing compounds have activity
against HIV-1. In studies of the antiretroviral activity of WR151327, a derivative of
amifostine, in chronically infected promonocytic cells, Kalebic and Schein [1994] reported
drug-associated inhibitory effects upon the viral reverse transcriptase. Bergamini et al.
[1994] studied the anti-HIV effects of cysteamine and its symmetrical diamine cystamine,
two compounds that are structurally related to WR1065; however, they failed to find
evidence of direct drug-associated effects upon the viral reverse transcriptase. Their studies
suggested that these two agents inhibited several stages of HIV replication including
assembly of infectious viral particles [Bergamini et al., 1994, 1996]. These thiol-containing
compounds also have been demonstrated to protect DNA from radiation-induced damage
[Allegra et al., 2002]; DNA protective effects could be related to an antimutagenic mode of
action. Taken together, these studies suggest that polyamines, polyamine analogs, and thiol-
containing compounds have a diverse range of activities. Although comparisons between
studies must be made with caution because different model systems were used to evaluate
drug-associated effects, it is noteworthy that no one mode of action described to date
appears to be adequate to explain the diversity of these effects.
Amifostine and its active form WR1065 have been studied for decades as radioprotectants,
and amifostine has been used clinically as a cytoprotectant since the mid-1990s. The range
of activities identified for this small compound include scavenging of free radicals,
cytoprotection against an array of physical agents and chemical compounds, and low-dose
effects that include changes in gene expression, and protection against mutagenesis,
neoplastic transformation, and metastasis. The pilot studies presented here add to this
diversity of effects by extending the range of its cytoprotective and antimutagenic effects
and by demonstrating in vitro antiviral activity against viruses classified in three distinct
groups, with diverse mechanisms involved in their replication, survival, and pathogenicity.
These findings show novel activities for WR1065 and support the conclusion that the amino-
thiols represent a new class of broad spectrum antiviral agents. These results indicate the
need for additional investigations of the mode of action for the antimutagenic and antiviral
activity of this drug.
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Abbreviations
AZT zidovudine or 3′-azido-2′,3′-dideoxythymidine
CE cloning efficiency
ddI didanosine or 2′,3′-dideoxyinosine
HPRT hypoxanthine-guanine phosphoribosyltransferase
NRTI nucleoside reverse transcriptase inhibitor
PBMCs peripheral blood mononuclear cells
PFUs plaque forming units
PHA phytohemagglutinin
SD standard deviation
WR1065 free thiol of amifostine
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Comparison of the induced mutant frequency at the HPRT locus of human TK6
lymphoblastoid cells exposed for 3 days to vehicle alone, 150 μM WR1065, 100 μM AZT-
ddI (equimolar), or 100 μM AZT-ddI (equimolar) plus 150 μM WR1065. Drug-induced
mutant frequencies were determined by subtracting the mean mutant frequency measured in
the vehicle-exposed group (mutant frequency = 2.8 × 10−6) from the mean observed mutant
frequency measured in individual treatment groups. An asterisk (*) designates that the mean
observed mutant frequency in AZT-ddI-exposed cells was significantly increased over the
mean (vehicle-exposed) control cell value (P < 0.05), whereas the double asterisk (**)
indicates that the mean observed mutant frequency in cells exposed to AZT-ddI plus
WR1065 was significantly reduced compared with cells exposed to AZT-ddI only (P < 0.05)
but was not significantly different from the mean observed value for vehicle-exposed cells.
WR1065 reduced the mutagenic effects of AZT-ddI by at least 85%. [Color figure can be
viewed in the online issue, which is available at www.interscience.wiley.com.]
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Titration of Ad4p infectious virus yields by plaque assay in A549 cell monolayers. Cells in
six-well plates were infected with 1000 PFU of Ad4p (RI-67) and treated with 0 or 100 μM
WR1065. After 1 hr adsorption, cells were replenished with minimum essential medium
containing 0 or 100 μM WR1065. At 7 days postinfection, infected cells were frozen and
freeze-thawed preparations were titered by standard plaque assay. Titers shown are from
Table III, experiment 1 except the mean virus yields are expressed as PFUs × 106/ml.
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Dose response for intracellular concentration of WR1065 following treatment of primary
mouse (A) or rat (B) lymphocytes for 1 or 2 hr with 0, 10, 50, or 100 μM amifostine
converted to WR1065 (n = 2–4/species for each exposure group). Amifostine was
dephosphorylated for 30 min with alkaline phosphatase to yield WR1065 for cell treatment.
A high-pressure liquid chromatography method with electrochemical detection was used to
measure WR1065, and the concentration of WR1065 per million cells in each sample was
determined by interpolating the peak areas to a standard curve for WR1065 [Pamujula et al.,
2004]. (A) Data from WR1065-exposed mouse lymphocytes; (B) data from WR1065-
exposed rat lymphocytes.
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TABLE I
Observed Cloning Efficiencies at 21 Days Following 3-Day Exposures of TK6 Cells to AZT-ddI (Equimolar)
and/or WR1065a
Treatment group CE (relative cell survival)b P-valuec
Vehicle-control 79 ± 10.9% (NA)d –
WR1065 (150 μM) 69.7 ± 5.3% (88%) 0.3
AZT-ddI (100 μM) 27.1 ± 11.0% (34%) <0.001
AZT-ddI (100 μM) + WR1065 (150 μM) 40.7 ± 13.0% (52%) 0.001
a
TK6 human lymphoblastoid cells were exposed to vehicle or the given concentrations of AZT-ddI and/or WR1065 for 3 days, and then washed,
diluted, and plated after a 7-day expression period under nonselection conditions to measure colony outgrowth as described in the Materials and
Methods. Plates were scored 14 days after plating to determine average cloning efficiency (CE).
b
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TABLE II
Inhibition of HIV-1 Replication as Assessed by Inhibition of p24 Protein Production in PHA-Stimulated
Human T-Cell Blasts by AZT and/or WR1065a
Exposure groups p24 protein (pg/ml) Estimated % inhibition
Experiment #1
Cells (uninfected) 0.28 NA
HIV-1-infected cells 498.62 NA
HIV-1-infected cells + 10 μM AZT 0.13b ~100%
HIV-1-infected cells + 1,000 μM WR1065 0.13b ~100%
HIV-1-infected cells + 10 μM AZT + 1,000 μM WR1065 0.13b ~100%
Experiment #2
Cells alone (uninfected) 8.99 NA
HIV-1-infected cells 176.45 NA
HIV-1-infected cells + 10 μM AZT 9.07b 94.9%
HIV-1-infected cells + 1,000 μM WR1065 8.92b 94.9%
HIV-1-infected cells + 330 μM WR1065 9.31b 94.7%
HIV-1-infected cells + 100 μM WR1065 8.92b 94.9%
Experiment #3
Cells alone (uninfected) 3.0 NA
HIV-1-infected cells 44,455.8 NA
HIV-1-infected cells + 10 μM AZT 2.9b ~100%
HIV-1-infected cells + 66 μM WR1065 33.2b 99.9%
HIV-1-infected cells + 33 μM WR1065 503.2b 98.9%
HIV-1-infected cells + 10 μM WR1065 911.2b 98.0%
HIV-1-infected cells + 5 μM WR1065 10,293.7b 76.8%
NA, not applicable.
a
Primary human lymphocytes were stimulated with PHA, and resulting T-cell blasts were infected with HIV-1BZ-167 for 2 hr, washed, and
treated with drug(s) for 72 hr, and then assessed for HIV p24 protein production using an ELISA kit as described in the Materials and Methods.
b
P < 0.001 (χ2 test), compared with p24 production in untreated HIV-infected cells.
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TABLE V
Average Infectious Virus Yield Reduction Per Unit Dose of WR1065 in Adenovirus or Influenza-Infected
Cells
Virus tested





Average # of PFUs
reduced by exposure to
WR1065 (×106)
PFUs reduced per unit
dose of WR1065 (×106)








AD4-P A549 0 (1,900)a NA
33 480 14.55
100 920 9.20









Average PFUs in vehicle-exposed cells.
NA, not applicable.
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